Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Warm Autoimmune Hemolytic Anemia
NCT05002777Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Sanofi. Started Dec 2021; status: active, not recruiting.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT05002777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002777.